Comprehensive Stock Comparison
Compare Nautilus Biotechnology, Inc. (NAUT) vs Regeneron Pharmaceuticals, Inc. (REGN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  REGN | Beta 0.58 vs NAUT's 1.71, lower leverage |
| Dividends | REGN | 0.4% yield; 1-year raise streak; NAUT pays no meaningful dividend |
| Momentum (1Y) |  NAUT | +118.3% vs REGN's +15.1% |
| Efficiency (ROA) | REGN | 11.1% ROA vs NAUT's -31.3% |
Who Each Stock Is For
Income & stability
REGNDividend streak 1 yrs, beta 0.58, yield 0.4%
Growth exposure
NAUTEPS growth 16.1%
Long-term compounding (10Y)
REGN94.0% 10Y total return vs NAUT's -74.9%
Sleep-well-at-night portfolio
REGNLower volatility, beta 0.58, Low D/E 8.7%, current ratio 4.77x
Defensive / Recession hedge
REGNBeta 0.58, yield 0.4%, current ratio 4.77x
Business Model
What each company does and how it makes money
Nautilus Biotechnology is a life sciences company developing a proteomics platform to analyze proteins at unprecedented scale and depth. It aims to generate revenue through sales of its integrated platform — including instruments, consumables, and software — though it remains pre-revenue as it develops its technology. The company's potential moat lies in its proprietary single-molecule protein analysis technology, which could enable comprehensive proteome mapping that existing methods cannot achieve.
Regeneron Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes innovative medicines for serious diseases. It generates revenue primarily from sales of its flagship products — EYLEA for eye diseases (~60% of revenue) and Dupixent for inflammatory conditions (~30%) — with additional income from collaborations and royalties. The company's competitive advantage lies in its proprietary VelocImmune technology platform for creating human antibodies and its deep expertise in genetic research, which enables rapid drug discovery and development.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
NAUT 3REGN 2NAUT1/1 metricsNAUT2/2 metricsREGN5/6 metricsNAUT4/6 metricsREGN2/2 metricsNAUT leads in 3 of 6 categories (Financial Metrics, Valuation Metrics). REGN leads in 2 (Profitability & Efficiency, Risk & Volatility).
Financial Metrics (TTM)
REGN and NAUT operate at a comparable scale, with $14.3B and $0 in trailing revenue.
| Metric | NAUTNautilus Biotechn… | REGNRegeneron Pharmac… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $14.3B |
| EBITDAEarnings before interest/tax | -$60M | $4.2B |
| Net IncomeAfter-tax profit | -$63M | $4.5B |
| Free Cash FlowCash after capex | -$54M | $3.2B |
| Gross MarginGross profit ÷ Revenue | — | +86.3% |
| Operating MarginEBIT ÷ Revenue | — | +25.7% |
| Net MarginNet income ÷ Revenue | — | +31.4% |
| FCF MarginFCF ÷ Revenue | — | +22.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +2.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +15.4% | -2.5% |
Valuation Metrics
| Metric | NAUTNautilus Biotechn… | REGNRegeneron Pharmac… |
|---|---|---|
| Market CapShares × price | $331M | $108.4B |
| Enterprise ValueMkt cap + debt − cash | $349M | $92.2B |
| Trailing P/EPrice ÷ TTM EPS | -5.57x | 18.99x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 17.38x |
| PEG RatioP/E ÷ EPS growth rate | — | 3.00x |
| EV / EBITDAEnterprise value multiple | — | 21.83x |
| Price / SalesMarket cap ÷ Revenue | — | 7.55x |
| Price / BookPrice ÷ Book value/share | 2.11x | 2.74x |
| Price / FCFMarket cap ÷ FCF | — | 26.56x |
Profitability & Efficiency
REGN delivers a 14.4% return on equity — every $100 of shareholder capital generates $14 in annual profit, vs $-37 for NAUT. REGN carries lower financial leverage with a 0.09x debt-to-equity ratio, signaling a more conservative balance sheet compared to NAUT's 0.19x. On the Piotroski fundamental quality scale (0–9), REGN scores 7/9 vs NAUT's 1/9, reflecting strong financial health.
| Metric | NAUTNautilus Biotechn… | REGNRegeneron Pharmac… |
|---|---|---|
| ROE (TTM)Return on equity | -37.1% | +14.4% |
| ROA (TTM)Return on assets | -31.3% | +11.1% |
| ROICReturn on invested capital | — | +12.4% |
| ROCEReturn on capital employed | — | +10.8% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 7 |
| Debt / EquityFinancial leverage | 0.19x | 0.09x |
| Net DebtTotal debt minus cash | $18M | -$16.2B |
| Cash & Equiv.Liquid assets | $12M | $18.9B |
| Total DebtShort + long-term debt | $30M | $2.7B |
| Interest CoverageEBIT ÷ Interest expense | — | 120.42x |
Total Returns (with DRIP)
A $10,000 investment in REGN five years ago would be worth $17,161 today (with dividends reinvested), compared to $1,808 for NAUT. Over the past 12 months, NAUT leads with a +118.3% total return vs REGN's +15.1%. The 3-year compound annual growth rate (CAGR) favors NAUT at 6.8% vs REGN's 0.5% — a key indicator of consistent wealth creation.
| Metric | NAUTNautilus Biotechn… | REGNRegeneron Pharmac… |
|---|---|---|
| YTD ReturnYear-to-date | +37.2% | +1.6% |
| 1-Year ReturnPast 12 months | +118.3% | +15.1% |
| 3-Year ReturnCumulative with dividends | +21.9% | +1.5% |
| 5-Year ReturnCumulative with dividends | -81.9% | +71.6% |
| 10-Year ReturnCumulative with dividends | -74.9% | +94.0% |
| CAGR (3Y)Annualised 3-year return | +6.8% | +0.5% |
Risk & Volatility
REGN is the less volatile stock with a 0.58 beta — it tends to amplify market swings less than NAUT's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. REGN currently trades 95.9% from its 52-week high vs NAUT's 85.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NAUTNautilus Biotechn… | REGNRegeneron Pharmac… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.71x | 0.58x |
| 52-Week HighHighest price in past year | $3.08 | $821.11 |
| 52-Week LowLowest price in past year | $0.62 | $476.49 |
| % of 52W HighCurrent price vs 52-week peak | +85.1% | +95.9% |
| RSI (14)Momentum oscillator 0–100 | 51.4 | 47.5 |
| Avg Volume (50D)Average daily shares traded | 197K | 762K |
Analyst Outlook
Wall Street rates NAUT as "Buy" and REGN as "Buy". Consensus price targets imply 8.8% upside for REGN (target: $857) vs -4.6% for NAUT (target: $3). REGN is the only dividend payer here at 0.43% yield — a key consideration for income-focused portfolios.
| Metric | NAUTNautilus Biotechn… | REGNRegeneron Pharmac… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $2.50 | $857.17 |
| # AnalystsCovering analysts | 5 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | +0.4% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $3.41 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | +3.2% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Aug 20 | Mar 26 | Change |
|---|---|---|---|
| Nautilus Biotechnol… (NAUT) | 100 | 22.22 | -77.8% |
| Regeneron Pharmaceu… (REGN) | 100 | 133.43 | +33.4% |
Regeneron Pharmaceu… (REGN) returned +72% over 5 years vs Nautilus Biotechnol… (NAUT)'s -82%. A $10,000 investment in REGN 5 years ago would be worth $17,161 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Nautilus Biotechnol… (NAUT) | $0.00 | $0.00 | — |
| Regeneron Pharmaceu… (REGN) | $4.9B | $14.3B | +195.1% |
Regeneron Pharmaceuticals, Inc.'s revenue grew from $4.9B (2016) to $14.3B (2025) — a 12.8% CAGR.
Chart 3P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Regeneron Pharmaceu… (REGN) | 36.4 | 18.6 | -48.9% |
Regeneron Pharmaceuticals, Inc. has traded in a 9x–36x P/E range over 9 years; current trailing P/E is ~19x.
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Nautilus Biotechnol… (NAUT) | 87.18 | -0.47 | -100.5% |
| Regeneron Pharmaceu… (REGN) | 7.7 | 41.48 | +438.7% |
Regeneron Pharmaceuticals, Inc.'s EPS grew from $7.70 (2016) to $41.48 (2025) — a 21% CAGR.
Chart 5Free Cash Flow — 5 Years
Nautilus Biotechnology, Inc. generated $-52M FCF in 2025 (-25% vs 2021). Regeneron Pharmaceuticals, Inc. generated $4B FCF in 2025 (-38% vs 2021).
NAUT vs REGN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NAUT or REGN a better buy right now?
Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 19.0x trailing P/E (17.4x forward), making it the more compelling value choice. Analysts rate Nautilus Biotechnology, Inc. (NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NAUT or REGN?
Over the past 5 years, Regeneron Pharmaceuticals, Inc. (REGN) delivered a total return of +71.6%, compared to -81.9% for Nautilus Biotechnology, Inc. (NAUT). A $10,000 investment in REGN five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: REGN returned +94.0% versus NAUT's -74.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NAUT or REGN?
By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc. (REGN) is the lower-risk stock at 0.58β versus Nautilus Biotechnology, Inc.'s 1.71β — meaning NAUT is approximately 197% more volatile than REGN relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 19% for Nautilus Biotechnology, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — NAUT or REGN?
Regeneron Pharmaceuticals, Inc. (REGN) is the more profitable company, earning 31.4% net margin versus 0.0% for Nautilus Biotechnology, Inc. — meaning it keeps 31.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 25.7% versus 0.0% for NAUT. At the gross margin level — before operating expenses — REGN leads at 86.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Is NAUT or REGN more undervalued right now?
Analyst consensus price targets imply the most upside for REGN: 8.8% to $857.17.
06Which pays a better dividend — NAUT or REGN?
In this comparison, REGN (0.4% yield) pays a dividend. NAUT does not pay a meaningful dividend and should not be held primarily for income.
07Is NAUT or REGN better for a retirement portfolio?
For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc. (REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.58)). Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1.71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +94.0%, NAUT: -74.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NAUT and REGN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.